Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction

Summary

Distal embolization is a relatively common complication in primary angioplasty and is associated with poor perfusion and higher mortality. The aim of this article is to critically review literature on pharmacological and mechanical therapies to prevent distal embolization in patients undergoing primary angioplasty. The literature was scanned by formal searches of electronic databases (MEDLINE, Pubmed) from January 1990 to March 2006 and scientific session abstracts (from January 1990 to March 2006) and oral presentation and/or expert slide presentations (from January 2002 to March 2006) (on TCT, AHA, ESC, ACC and EuroPCR websites). No language restrictions were enforced. Several pharmacological and mechanical therapies have been investigated to prevent distal embolization.Abciximab has been shown to reduce mortality,and its early admin-istration may provide additional benefits in outcome due to improvement in preprocedural reperfusion.The results of randomized trials on adjunctive mechanical devices remain controversial. Even though they reduce distal embolization and improve myocardial perfusion, no benefits have been observed in terms of 30-day survival. Adjunctive abciximab has improved survival, and its early administration is to be recommended, particularly when transportation to a primary PCI center is needed. Pending the results of large randomized trials with long-term follow-up data, the routine use of adjunctive mechanical devices to prevent distal embolization cannot be recommended, though selective use of these devices might be considered when large thrombotic burden is present.

Keywords

Acute myocardial infarction - prevention - GP IIb/IIIa - coronary syndrome

• References

• 1 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
• 2 Zhu MM, Feit A, Chadow H. et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-301.
• 3 De Luca G, Suryapranata H, Stone GW. et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a metaanalysis of randomized trials. J Am Med Assoc 2005; 293: 1759-65.
• 4 van t’ AHof, Liem A, Suryapranata H. et al. on the behalf of the Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Myocardial Blush Grade. Circulation 1998; 97: 2302-6.
• 5 Stone GW, Peterson MA, Lansky AJ. et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39: 591-7.
• 6 De Luca G, van’t AWHof, Ottervanger JP. et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 2005; 150: 557-62.
• 7 Sakuma T, Leong-Poi H, Fisher NG. et al. Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli. J Am Soc Echocardiogr 2003; 16: 15-21.
• 8 Limbruno U, De Carlo M, Pistolesi S. et al. Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J 2005; 150: 102-8.
• 9 Yip HK, Chen MC, Chang HW. et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 2002; 122: 1322-32.
• 10 Kotani J, Mintz GS, Pregowski J. et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 2003; 92: 728-32.
• 11 Stone GW, Webb J, Cox DA. et al Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. J Am Med Assoc 2005; 293: 1063-72.
• 12 Henriques JP, Zijlstra F, Ottervanger JP. et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23: 1112-7.
• 13 Napodano M, Tarantini T, Compagno S. et al. Predictors of distal embolization during direct angioplasty for acute myocardial infarction. Am J Cardiol 2005; 96 (Suppl 7A) 5H.
• 14 Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am HeartJ 1999; 138: S1-5.
• 15 Schwarz M, Nordt T, Bode C. et al. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res 2002; 107: 121-8.
• 16 Neumann FJ, Blasini R, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-701.
• 17 Petronio AS, Rovai D, Musumeci G. et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003; 24: 67-76.
• 18 Stone G, Grines CL, Cox AD. et al for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N EnglJ Med 2002; 346: 957-66.
• 19 Costantini CO, Stone GW, Mehran R. et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004; 44: 305-12.
• 20 Brener SJ, Ban LA, Burchenal JEB. et al on the behalf of the RAPPORT investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-41.
• 21 Neumann FJ, Kastrati A, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-21.
• 22 Montalescot G, Barragan P, Wittemberg O. et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-903.
• 23 Petronio AS, Musumeci G, Limbruno U. et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 2002; 143: 334-41.
• 24 Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002; 90: 533-6.
• 25 Lee CW, Moon DH, Hong MK. et al. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002; 90: 1243-6.
• 26 Antoniucci D, Rodriguez A, Hempel A. et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879-85.
• 27 Steen H, Lehrke S, Wiegand UK. et al. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. Am Heart J 2005; 149: 564.
• 28 Ernst NM, Suryapranata H, Miedema K. et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 1187-93.
• 29 Petronio AS, De Carlo M, Ciabatti N. et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005; 150: 1015.
• 30 De Luca G, Suryapranata H, Stone GW. et al. Relationship between patient’s risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol 2006; 47: 685-6.
• 31 De Luca G, Smit JJ, Ernst N. et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005; 93: 820-3.
• 32 Bellandi F, Maioli M, Gallopin M. et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004; 62: 186-92.
• 33 De Luca G, Suryapranata H, Ottervanger JP. et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109: 1223-5.
• 34 De Luca G, van’t AWHof, de Boer MJ. et al. Timeto-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 2004; 25: 1009-13.
• 35 Tarantini G, Cacciavillani L, Corbetti F. et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrastenhanced magnetic resonance. J Am Coll Cardiol 2005; 46: 1229-35.
• 36 van’t AWHof, Ernst N, de Boer MJ. et al On-TIME study group. Facilitation of primary coronary angioplasty by early start ofa glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004; 25: 837-46.
• 37 Zeymer U, Zahn R, Schiele R. et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005; 26: 1971-7.
• 38 Cutlip DE, Ricciardi MJ, Ling FS. et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003; 92: 977-80.
• 39 Lee DP, Herity NA, Hiatt BL. et al. TIrofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107: 1497-501.
• 40 Bellandi F, Maioli M, Leoncini M. et al. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 2006; 108: 36-42.
• 41 Arntz HR. et al. Is early prehospital administration of abciximab superior to periprocedural theapy in patients with STEMI and planned PCI? Early and late results from the randomized REOMOBILE Pilot study. JACC. 2004 43. Suppl A.
• 42 Gabriel MH. et al. Early administration of abciximab bolus in the emergency room improves microperfusion after primary coronary intervention, as assessed by TIMI frame count; results of the ERAMI trial. EHJ. 2003 24. (Suppl): 543 (Abstract).
• 43 Gyongyosi M, Domanovits H, Benzer W. et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarctrelated artery and improved myocardial tissue reperfusion – results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 2004; 25: 2125-33.
• 44 Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 19: 1065-9.
• 45 O’Neill WW, Weintraub R, Grines CL. et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992; 86: 1710-7.
• 46 Widimsky P, Groch L, Zelizko M. et al. Multicentre randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting toa community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000; 21: 823-31.
• 47 Vermeer F, Oude AJOphuis, vd EJBerg. et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82: 426-31.
• 48 Ross AM, Coyne KS, Reiner JS. et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogenactivator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999; 34: 1954-62.
• 49 Fernandez-Aviles F, Alonso JJ, Castro-Beiras A. et al. Primary versus facilitated percutaneous coronary intervention (tenecteplase plus stenting) in patients with ST-elevated myocardial infarction: the final results of the GRACIA-2 randomized trial. Eur Heart J. 2004 25. (Suppl): 33 (Abstract).
• 50 Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI):randomised trial Assessment of the Safety and Efficacy ofa New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Lancet 2006; 367: 569-78.
• 51 Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367: 579-88.
• 52 Antman EM, Louwerenburg HW, Baars HF. et al. Enoxaparin as adjunctive antithrombin therapy for STelevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105: 1642-9.
• 53 De Luca G, Ernst N, Zijlstra F. et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43: 1363-7.
• 54 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-73.
• 55 Rittersma SZ, van der Wal AC. et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation 2005; 111: 1160-5.
• 56 Carlino M, De Gregorio J, Di Mario C. et al. Prevention of distal embolization during saphenous vein graft lesion angioplasty. Experience with a new temporary occlusion and aspiration system. Circulation 1999; 99: 3221-3.
• 57 Stone GW, Rogers C, Ramee S. et al. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002; 40: 1882-8.
• 58 Limbruno U, Micheli A, De Carlo M. et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003; 108: 171-6.
• 59 Fujita N, Suwa S, Koyama S. et al. The efficacy of distal embolic protection device during an acute myocardial infarction: Early and long-term results. Am J Cardiol 2004; 94 (Suppl 6A) 34E.
• 60 Gick M, Jander N, Bestehorn HP. et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005; 112: 1462-9.
• 61 Guetta V, UPFLOW MI. A randomized filterwire in primary PCI. Oral presentation TCT 2005. October 16-21 2005. Washington, DC.:
• 62 Grube E, Gerckens U, Yeung AC. et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001; 104: 2436-41.
• 63 Lefevre T, Guyon P, Reimers B. et al. Evaluation of a distal protection filter device in patients with acute myocardial infarction: The DIPLOMAT Study. Am J Cardiol. 2003 (Suppl 6A).
• 64 Nanasato M, Hirayama H, Muramatsu T. et al. Impact of angioplasty with distal protection device on myocardial reperfusion. J Am Coll Cardiol 2004; (Suppl): 246A
• 65 Rhee I, Gwon HC, Choi JH. et al. Distal Protection reduces infarct size after primary angioplasty in acute myocardial infarction: magnetic resonance imaging. Am J Cardiol 2004; (Suppl) 36E.
• 66 Tahk S-J, Chae IH, Choi S-Y. et al. The effect of distal protection on the protection of microvascular integrity during primary stenting in AMI without glycoprotein IIb/IIIa inhibition. Circulation. 2004 110. (Suppl): (Abstract).
• 67 Hong GR, Kang JH, Bae JH. et al. Effectiveness of distal protection device on the protection of microvascular integrity assessed by myocardial contrast echocardiography in patients with acute myocardial infarction. Eur Heart J. 2005 26. (Suppl): 347 (Abstract).
• 68 Wang JC, Normand SL, Mauri L. et al. Coronary artery spatial distribution of acute myocardial infarction occlusion. Circulation 2004; 110: 278-84.
• 69 Sievert H, Wahr DW, Schuler G. et al. Effectiveness and safety of the Proxis system in demonstrating retrograde coronary blood flow during proximal occlusion and in capturing embolic material. Am J Cardiol 2004; 94: 1134-9.
• 70 Kock K, De Winter RJ, Henriques JPS. et al. Combined embolic protection and thrombectomy in percutaneous coronary intervention for acutre myocardial infarction: preliminary results using the Proxis device. Am J Cardiol 2004; 94 (Suppl 6A) 25E.
• 71 Beran G, Lang I, Schreiber W. et al. Intracoronary thrombectomy with the X-sizer catheter system improves epicardial flow and accelerates ST-segment resolution in patients with acute coronary syndrome: a prospective, randomized, controlled study. Circulation 2002; 105: 2355-60.
• 72 Napodano M, Pasquetto G, Sacca S. et al. Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1395-402.
• 73 Dudek D, Mielecki W, Legutko J. et al. Percutaneous thrombectomy with the RESCUE system in acute myocardial infarction. Kardiol Pol 2004; 61: 523-33.
• 74 Antoniucci D, Valenti R, Migliorini A. et al. Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2004; 93: 1033-5.
• 75 Kuni H, Kijima M, Araki T. et al. Lack of efficacy of intracoronary thrombus aspiration before coronary stenting in patients with Acute Myocardial Infarction: A Multicenter Randomized Trial. JACC 2004; (Suppl) 245A.
• 76 Lefèvre T, Garcia E, Reimers B. et al. X-sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution: results of the X-sizer in AMI for neglible embolization and optimal ST resolution (X AMINE ST) trial. J Am Coll Cardiol 2005; 46: 246-52.
• 77 Arshad A, Cox D, Dib N. et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 2006; 48: 244-52.
• 78 Burzotta F, Trani C, Romagnoli E. et al. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol 2005; 46: 371-6.
• 79 Noel B, Morice MC, Lefevre T. et al. Thromboaspiration in acute ST-elevation MI improves myocardial reperfusion. Circulation 2005; 112 (Suppl II) 519.
• 80 Kaltoft A, Bøttcher M, Nielsen S. et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment–elevation myocardial infarction: A randomized, controlled trial. Circulation 2006; 114: 40-7.
• 81 Colombo P, Silva P, Bigi R. et al. Thrombus aspiration improves coronary flow and Myocardial reperfusion in acute myocardial infarction: final results of the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. Am J Cardiol. 2005 96. (Suppl): 74H (Abstract).
• 82 Ikari Y, Kawano S, Sakurada M. et al. Thrombus aspiration prior to coronary intervention improves myocardial microcirculation in patients with ST elevation acute myocardial infarction, the VAMPIRE Study. Circulation 2005; 112 (Suppl II) 659.
• 83 De Luca L, Sardella G, Davidson CJ. et al. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST-elevation myocardial infarction. Heart 2006; 92: 951-7.
• 84 Bolognese L, Carrabba N, Parodi G. et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109: 1121-6.
• 85 Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22: 729-39.